Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1

Yuki Ikematsu, Yasuto Yoneshima, Kayo Ijichi, Kentaro Tanaka, Taishi Harada, Yoshinao Oda, Yoichi Nakanishi, Isamu Okamoto

研究成果: ジャーナルへの寄稿レター

5 引用 (Scopus)
元の言語英語
ページ(範囲)230-231
ページ数2
ジャーナルLung Cancer
112
DOI
出版物ステータス出版済み - 10 1 2017

Fingerprint

Carcinoma
Lung
pembrolizumab

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

これを引用

Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1. / Ikematsu, Yuki; Yoneshima, Yasuto; Ijichi, Kayo; Tanaka, Kentaro; Harada, Taishi; Oda, Yoshinao; Nakanishi, Yoichi; Okamoto, Isamu.

:: Lung Cancer, 巻 112, 01.10.2017, p. 230-231.

研究成果: ジャーナルへの寄稿レター

@article{2ac68d48562141bf911a4e63ee1aba18,
title = "Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1",
author = "Yuki Ikematsu and Yasuto Yoneshima and Kayo Ijichi and Kentaro Tanaka and Taishi Harada and Yoshinao Oda and Yoichi Nakanishi and Isamu Okamoto",
year = "2017",
month = "10",
day = "1",
doi = "10.1016/j.lungcan.2017.07.020",
language = "English",
volume = "112",
pages = "230--231",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1

AU - Ikematsu, Yuki

AU - Yoneshima, Yasuto

AU - Ijichi, Kayo

AU - Tanaka, Kentaro

AU - Harada, Taishi

AU - Oda, Yoshinao

AU - Nakanishi, Yoichi

AU - Okamoto, Isamu

PY - 2017/10/1

Y1 - 2017/10/1

UR - http://www.scopus.com/inward/record.url?scp=85025826776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025826776&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2017.07.020

DO - 10.1016/j.lungcan.2017.07.020

M3 - Letter

VL - 112

SP - 230

EP - 231

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -